SHANGHAI, July 2, 2024
/PRNewswire/ -- Pulnovo Medical Limited, a globally recognized
device pioneer in the treatment of Pulmonary Hypertension (PH) and
Heart Failure (HF), is pleased to announce the successful
initiation and first two patients enrollment for its
global multicenter clinical study exploring the percutaneous
pulmonary artery denervation (PADN) treatment for pulmonary
hypertension associated with left heart disease. This
landmark event took place at Centro Hospitalar Universitário de
Lisboa Central - Hospital de Santa
Marta in Portugal, marking
the beginning of Pulnovo Medical's innovative product deployment on
a global scale.
Under the guidance of Professor Hang
Zhang from Nanjing Medical University Affiliated Nanjing
Hospital, Prof. Ruben Ramos and his
team successfully performed the PADN procedure on two patients. The
procedure was smooth, the devices easy to operate, and the results
were excellent. The Portuguese medical team was impressed by the
PADN technology's safety and efficacy, as demonstrated by many
years of data. Clinical parameters showed promising
results when using PADN technology. The products' comprehensive
design and high-precision algorithm control significantly ensured
stable energy output and effective surgical results.
Prof. Ruben Ramos
said, "PADN technology shows great
potential in treating pulmonary hypertension associated with left
heart disease. We are delighted to be the first in Europe to participate in this global clinical
study. Our team is confident in this project and looks forward to
bringing more treatment options to European pulmonary hypertension
patients through this study. PADN is not only a new treatment
method but also brings new hope to patients suffering from
pulmonary hypertension."
Jessie
Lian,Pulnovo Medical's CEO said,
"The PADN global multicenter clinical study is one of our
key projects dedicated to innovative treatment technologies in the
cardiovascular field. As an emerging treatment, PADN has enormous
potential and prospects. The
post-operative results of the first overseas application
of PADN reflect the academic borderlessness of the moment. In
the future, we will continue to firmly advance our global business,
steadily promoting the teaching and learning of PADN technology. "
Cynthia Chen, Pulnovo
Medical's Chairlady said, "We are
proud to have successfully completed the first enrollment in the
European multicenter clinical study of PADN in Portugal, marking the acceleration of our
technology's global progress. We will continue to promote the
global application of PADN, allowing more patients to benefit from
this innovative therapy."
View original
content:https://www.prnewswire.com/news-releases/pulnovo-medical-announces-first-enrollment-in-portugal-for-global-clinical-study-of-padn-technology-in-treating-pulmonary-hypertension-associated-with-left-heart-disease-302187937.html
SOURCE Pulnovo Medical